---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-024088"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:43:49.247692+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elite Q1 revenue $40.2M, up 114% YoY; operating profit $21.7M, up 462%

## Summary
- Consolidated revenues of $40.2M for Q1 FY2026, a 114% increase YoY from the prior year comparable period.
- Operating profits of $21.7M, a 462% increase YoY, driven by sales of lisdexamfetamine products and strong Elite label growth.
- Lisdexamfetamine products launched after the prior year Q1, contributing significantly to the top-line expansion.
- Company will host a conference call on August 15, 2025 at 11:30 AM EDT to discuss results and provide a business update.

## SEC filing metadata
- accession: 0001641172-25-024088
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000164117225024088/0001641172-25-024088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000164117225024088/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-024088
- JSON: https://secwatch.observer/filing/0001641172-25-024088.json
- Plain text: https://secwatch.observer/filing/0001641172-25-024088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.